Fen-Phen Lawyer, Fen-Phen Attorney
At this time, Pulaski & Middleman, LLC has successfully resolved all of its Fen-Phen cases. We represented more than 400 individuals injured by taking Fen-Phen. The total value of our clients settlement was more than $ 40,000,000.00 (Forty Million Dollars)
Fen-Phen
Fen Phen, or Pondimin (generic name: fenfluramine) and Redux (generic name: dexfenfluramine) has been linked to heart valve disease and Primary Pulmonary Hypertension. Fen Phen was a popular weight loss and appetite suppressant drug prescribed to people wanting to lose weight.
In 1997 the FDA asked American Home Products the makers of Pondimin (Fenfluramine) and Redux (Dexfenfluramine), to withdraw its popular anti-obesity drugs from the market. American Home Products Corp. of Madison, N.J., manufactured fenfluramine under the brand name Pondimin and an American Home Product’s subsidiary Wyeth-Ayerst Laboratories, manufactured Dexfenfluramine for Interneuron Pharmaceuticals, which was marketed under the name of Redux. Medical studies have linked Pondimin or Redux to heart valve disease.
The FDA stated that in findings from doctors who evaluated patients that took Fenfluramine and Dexfenfluramine with echocardiograms, that approximately 30 percent of patients who were evaluated had abnormal echocardiograms, even though they had no symptoms. This is a much higher than expected percentage of abnormal test results.
Additionally, a Mayo Clinic study that was published in the New England Journal of Medicine on August 28, 1997 suggested that as high as one-third of a patient sampling of Fen-Phen diet pill users had evidence of heart valve disease. The study found that there was a high incidence of heart valve disease in patients taking these diet pills, without any other known reason for valve disease.
In addition to heart valve disease, the use of fenfluramine and dexfenfluramine has been found to increase the risk of developing Primary Pulmonary Hypertension or (PPH). PPH is a rare disease of that causes the progressive narrowing of the blood vessels of the lungs. Studies estimate that treatment with certain appetite suppressant drugs tends to increase the chances of developing PPH by approximately 25 to 30 percent.
Each state has a law which limits the amount of time an injured person has to file a lawsuit after the injury. The amount of time can vary greatly for many reasons. Pulaski & Middleman is no longer accepting Fen-Phen cases. If you have any questions, please feel free to contact us at 1-800-BAD-DRUG.
Note – Do not stop taking any medications without first consulting your doctor.
